Carcinoma of Unknown Primary Clinical Trial
Official title:
A Randomized Phase III Trial of Paclitaxel, Carboplatin and Etoposide Vs. 5-Fluorouracil and Folinic Acid in the Treatment of Patients With Adenocarcinoma of Unknown Primary Site
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells. It is
not yet known which combination chemotherapy regimen is more effective for cancer of unknown
primary origin.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens
of combination chemotherapy in treating patients with cancer of unknown primary origin.
OBJECTIVES:
- Compare the overall survival after treatment with paclitaxel, carboplatin, and
etoposide and after treatment with fluorouracil and leucovorin calcium in patients with
adenocarcinoma of unknown primary.
- Compare the response rates, progression free survival, toxicity profile, and quality of
life between the two regimens in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by center and
presence or absence of liver metastases.
Patients are randomly assigned to one of two treatment arms.
- Arm I: Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on
day 1, and oral etoposide on days 1-10. Treatment is repeated every 3 weeks for up to
four courses.
- Arm II: Patients receive leucovorin calcium IV over 2 hours followed by fluorouracil IV
over 24 hours weekly for 6 weeks. Treatment is repeated every 7 weeks for up to two
courses.
Patients are followed every 3 months after treatment for 1 year or until death. Quality of
life questionnaires are completed at each follow-up.
PROJECTED ACCRUAL: Approximately 120-140 patients will be accrued for this study within 3
years.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00003943 -
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.
|
Phase 2 | |
| Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
| Recruiting |
NCT02590055 -
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
|
Phase 2 | |
| Completed |
NCT00002507 -
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
| Recruiting |
NCT03740503 -
Genomic Investigation of Unusual Responders
|
||
| Terminated |
NCT00148135 -
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site
|
Phase 2 | |
| Completed |
NCT00003582 -
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00014456 -
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Completed |
NCT00357630 -
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
|
Phase 2 | |
| Active, not recruiting |
NCT01366144 -
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
| Completed |
NCT00004922 -
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
|
Phase 2 | |
| Recruiting |
NCT05887492 -
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00119314 -
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
|
Phase 2 | |
| Completed |
NCT00047125 -
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
|
Phase 3 | |
| Completed |
NCT00003657 -
High-dose ICE With Amifostine
|
Phase 2 | |
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Recruiting |
NCT02764216 -
Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary
|
Phase 2 | |
| Completed |
NCT00873119 -
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
|
Phase 2 | |
| Completed |
NCT00388024 -
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
|
N/A |